Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 1
2002 5
2003 3
2004 3
2005 4
2006 7
2007 14
2008 18
2009 20
2010 21
2011 30
2012 42
2013 53
2014 42
2015 43
2016 35
2017 37
2018 37
2019 42
2020 65
2021 55
2022 25
Text availability
Article attribute
Article type
Publication date

Search Results

544 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review.
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently approved as the first oncolytic virus drug in the USA and Europe. ...It appears that it will not be long before oncol
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was rec …
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.
In particular, recombinant vaccinia viruses (VV) hold great promise as interventional agents. In this article, we first summarize the current understanding of virus biology and viral genes involved in host-virus interactions to further improve the utility of …
In particular, recombinant vaccinia viruses (VV) hold great promise as interventional agents. In this article, we first summarize the …
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S, Fukuhara H, Todo T. Taguchi S, et al. Jpn J Clin Oncol. 2019 Mar 1;49(3):201-209. doi: 10.1093/jjco/hyy170. Jpn J Clin Oncol. 2019. PMID: 30462296 Review.
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug approval: Pexa-Vec (pexastimogene devacirepvec), an oncolytic vaccinia virus, CG0070, an oncolytic adenovirus, and …
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug ap …
Oncolytic Vaccinia Virus in Lung Cancer Vaccines.
Truong CS, Yoo SY. Truong CS, et al. Vaccines (Basel). 2022 Feb 4;10(2):240. doi: 10.3390/vaccines10020240. Vaccines (Basel). 2022. PMID: 35214699 Free PMC article. Review.
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) …
Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adver …
Oncolytic vaccinia virus for the treatment of cancer.
Guse K, Cerullo V, Hemminki A. Guse K, et al. Expert Opin Biol Ther. 2011 May;11(5):595-608. doi: 10.1517/14712598.2011.558838. Epub 2011 Feb 22. Expert Opin Biol Ther. 2011. PMID: 21338330 Review.
AREAS COVERED: This review describes the use of vaccinia virus in cancer therapy as a gene therapy vector, as an oncolytic virus and in the generation of oncolysates. ...EXPERT OPINION: Vaccinia virus has great potential in cancer gene th …
AREAS COVERED: This review describes the use of vaccinia virus in cancer therapy as a gene therapy vector, as an oncolytic
Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells.
Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso NC, Rodriguez Cruz T, Wu MF, Liu H, Song XT, Suzuki M, Wang LL, Yustein JT, Gottschalk S. Cao F, et al. Adv Cell Gene Ther. 2021 Apr;4(2):e99. doi: 10.1002/acg2.99. Epub 2020 Jul 3. Adv Cell Gene Ther. 2021. PMID: 33829146 Free PMC article.
Oncolytic virotherapy has been tested in numerous early phase clinical studies. ...We engineered an oncolytic vaccinia virus (VV) to disrupt the CD47/SIRPalpha interaction by expressing a chimeric molecule that consists of the ectodomain of SIRPalpha a
Oncolytic virotherapy has been tested in numerous early phase clinical studies. ...We engineered an oncolytic vaccinia
Generation of a Novel Oncolytic Vaccinia Virus Using the IHD-W Strain.
Shin J, Hong SO, Kim M, Lee H, Choi H, Kim J, Hong J, Kang H, Lee E, Lee S, Kong B, Kim M, Choi H, Kim S. Shin J, et al. Hum Gene Ther. 2021 May;32(9-10):517-527. doi: 10.1089/hum.2020.050. Epub 2020 Oct 15. Hum Gene Ther. 2021. PMID: 32854548 Free PMC article.
As an oncolytic virus platform, vaccinia virus has unique advantages, including rapid replication, a broad range of host targets, and a large capacity for transgene incorporation. In this study, we developed a novel oncolytic vaccinia
As an oncolytic virus platform, vaccinia virus has unique advantages, including rapid replication, a broad range …
Oncolytic Vaccinia Virus Harboring Aphrocallistes vastus Lectin Inhibits the Growth of Cervical Cancer Cells Hela S3.
Ni J, Feng H, Xu X, Liu T, Ye T, Chen K, Li G. Ni J, et al. Mar Drugs. 2021 Sep 23;19(10):532. doi: 10.3390/md19100532. Mar Drugs. 2021. PMID: 34677432 Free PMC article.
Our previous study demonstrated that genes encoding AVL enhanced the cytotoxic effect of oncolytic vaccinia virus (oncoVV) in a variety of cancer cells. In this study, the inhibitory effect of oncoVV-AVL on Hela S3 cervical cancer cells, a cell line with sphe …
Our previous study demonstrated that genes encoding AVL enhanced the cytotoxic effect of oncolytic vaccinia virus (onco …
An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z, Liu B, Huang C, Xie W, Cen Y, Chen L, Liang M. Shi Z, et al. Biochem Biophys Res Commun. 2021 Jun 25;559:176-182. doi: 10.1016/j.bbrc.2021.04.078. Epub 2021 May 1. Biochem Biophys Res Commun. 2021. PMID: 33945995
Oncolytic virus can selectively recognize cancer cells, target tumors, and stimulate an oncolytic and immune response. Recombinant armed oncolytic vaccinia virus has emerged as an attractive tool in oncolytic virotherapy because it
Oncolytic virus can selectively recognize cancer cells, target tumors, and stimulate an oncolytic and immune response.
Oncolytic cancer therapy with a vaccinia virus strain.
Deng L, Fan J, Ding Y, Zhang J, Zhou B, Zhang Y, Huang B, Hu Z. Deng L, et al. Oncol Rep. 2019 Jan;41(1):686-692. doi: 10.3892/or.2018.6801. Epub 2018 Oct 16. Oncol Rep. 2019. PMID: 30365140
Oncolytic vaccinia virus is currently undergoing evaluation as a biological anticancer agent in clinical trials. ...However, the efficacy as oncolytic virotherapy of Chinese vaccinia strain Tian Tan (VTT) has not been reported. ...
Oncolytic vaccinia virus is currently undergoing evaluation as a biological anticancer agent in clinical trials. ...How
544 results